# Safety, Tolerability, and Efficacy of Zilucoplan in Subjects With Generalized Myasthenia Gravis

> **NCT04115293** · PHASE3 · COMPLETED · sponsor: **Ra Pharmaceuticals, Inc.** · enrollment: 174 (actual)

## Conditions studied

- Myasthenia Gravis, Generalized

## Interventions

- **DRUG:** zilucoplan (RA101495)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04115293
- **Lead sponsor:** Ra Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-09-17
- **Primary completion:** 2021-12-30
- **Final completion:** 2021-12-30
- **Target enrollment:** 174 (ACTUAL)
- **Last updated:** 2025-07-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04115293

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04115293, "Safety, Tolerability, and Efficacy of Zilucoplan in Subjects With Generalized Myasthenia Gravis". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04115293. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*